The second case is a three-yr-old girl, from Birjand, South Khorasan, and Iran. This patient is the cousin of the first case. She is the second child of non-related parents. The older sibling is healthy. The patient had birth weight of 2400 gr, height of 49 cm, and head circumference of 34 cm. By the age of nine months, she was developmentally normal and could sit and crawl. At the age of seven months, she was examined due to irritability and anemia pulse splenomegaly was diagnosed (ultrasonography showed spleen size of 108 mm and normal echo). Since the age of nine months, she developmentally regressed and never obtained the capability of independent walking and talking. Liver function tests were normal and mild hypochromic microcytic anemia was detected in peripheral smear. The high-performance liquid chromatography of serum amino acids and MS/MS examinations, and enzyme assay for lipid storage disease was normal and in BMA, foamy cells were noted. In neurological examination, spasticity, platter dystopia, dysphagia, and clumsiness were observed. The patient also had history of frequent focal and generalized seizures controlled by antiepileptic drugs. In abdominal examination, splenomegaly extended to the pelvis and Vertical supranuclear gaze palsy was detected. During the recent months, hypotonia after laughter and gelastic cataplexy were observed. Considering neurovascular symptoms, family history, and high NPC risk prediction scores, she was studied for NPC gene mutation and the diagnosis confirmed. The third case is an 11-months-old boy from the same area, Birjand, South Khorasan, Iran. He is the first offspring of a consanguineous marriage. Due to mild hypochromic, microcytic anemia and splenomegaly were investigated. Liver function tests and enzyme assay for lipid storage disease was normal and foam cells were reported in BMA. He was developmentally age-appropriate. He could crawl and stand with help and speak 1-2 words. Neurological examination of the eye was normal and NPC risk prediction score was 55. He underwent genetic analysis, as well. (Order no: 62266939, Centogene Company) In all the three cases, NPC-509 was pathologically increased; they also had an unreported homozygous mutation (c.1415T>C, p.Leu472Pro) in exon 9 of the
Case report
The first case is a 3.75-yr old boy, referred to the Imam Reza Hospital, Pediatric Endocrinology and Metabolic Service, Mashhad, Iran in 2016. The patient is the first offspring of a first-cousin marriage from Birjand, South Khorasan, Iran, with birth weight of 2250 gr, 47 cm height, and head circumference of 34 cm. The patient had a history of neonatal jaundice from 40 days earlier.
Developmental milestones were delayed, the head holding was at five months, at nine months he was able to sit independently, and at the age of two years, he started to walk on feet. At six months, the patient was admitted to hospital due to gastroenteritis, and abdominal examination demonstrated splenomegaly. Cell blood count and liver transaminase function tests were normal and peripheral blood smear had no pathological finding. In fundoscopy, cherry red spot was not detected. For further investigation, bone marrow aspiration was performed, which exhibited foamy cells. Thereafter, enzyme assay was carried out, reporting normal activity of glucuronidase, galactokinase, and sphingomyelinase. There was no problem until 2.5 yr of age when he went to kindergarten. Speech and learning were acceptable; however, from the age of three, he started to suffer from ataxia and frequent falling, impaired speech, and dysphagia. At referral, spasticity, cerebellar dysfunction, dystonia, and splenomegaly were noted. At the age of two, enzyme assay was re-performed, which was normal, but with probable diagnosis of Gaucher's disease, enzyme replacement therapy was carried out for eight months. However, developmental regression trend was accelerated in the recent months and currently, he is not able to walk, sit, or swallow. He has no history of seizure or hearing impairment. Electroencephalogram revealed generalized sharp waves and in magnetic resonance imaging, sulcal widening and frontoparietal furrows were reported. Eye examination was abnormal and vertical supranuclear gaze palsy was detected. Moreover, in ultrasonography, spleen size was 41*122 with normal echo pattern and without hepatomegaly. Considering the combination of systemic and neurological symptoms and risk prediction score of higher than 70, NPC was suspected, accordingly, genetic analysis was performed and the diagnosis confirmed. (Order no: 62262135, Centogene Company) and strongest indicator of NPC, is seen in 66% of patients. VSGP accompanied with other signs such as splenomegaly and ataxia is highly predictive of NPC, observed in every two patients with neurological symptoms (1). Gelastic cataplexy is characterized by episodes of cataplexy, and is one of the most powerful predictive factors of NPC, observed in one of our patients. BMA was carried out in each of the three patients due to splenomegaly, demonstrating foam cells. Moreover, enzyme assay showed normal activity of sphingomyelinase; in NPC, activity of this enzyme is normal despite A and B types. Based on systemic and neurological symptoms and through NPC risk prediction score, If NPC is strongly suspected, mutation of NPC-1 and NPC-2 genes must be investigated, which is not only important for documentation, but also for prenatal diagnosis and carrier identification (4) . In all the three cases, NPC-509 was pathologically increased; they also had an unreported homozygous mutation (c.1415T>C, p.Leu472Pro) in exon 9 of the NPC1 gene. It is located in a weakly conserved nucleotide and highly conserved amino acid position, with moderate physicochemical differences between the amino acids leucine and proline. Software analysis by Polyphen -2, SIFT and Mutation Taster predict this variant is probably damaging. To date, this variant is not described in the Exome Aggregation Consortium, Exome Sequencing Project or the 100 Genomes Browser. The current number for identified NPC1 disease-causing mutations is near to 300. In the NPC1 gene, one mutant allele, p.I1061T, is the most common (approximately 20%-25% of alleles in patients diagnosed in France or the United Kingdom) (1). In the homoallelic state, it correlates with a juvenile neurologic onset form of the disease. The second common NPC1 mutation in Europe is p.P1007A. "The mutation p.G992W, typical of NovaScotian patients is sporadically found (but rarely) in patients of another origin" (7) . For NPC, it has been possible to make genotype-phenotype correlations that predict disease severity and allow more precise genetic counseling (8) . The genotype -phenotype studies in NP-C1 patients NPC1 gene.
Discussion

